Introduction
BK, a nonapeptide generated in plasma and tissues by activation of kininogens, exerts its effects through the constitutively expressed B 2 receptor before degradation by enzymatic cleavage. The des-Arg 9 metabolites of BK maintain a biological activity mediated by the B 1 receptor, which is not or barely expressed in normal tissues, but it is up-regulated following inflammation and tissue injury (Leeb-Lundberg et al., 2005) .
In humans and guinea-pigs, the kinin B 2 receptors are present in lungs (Mak and Barnes, 1991) and nasal airways (Dear et al., 1996; Fujiwara et al., 1989) . In guineapig airways, BK induces bronchoconstriction (Wirth et al., 1993) , microvascular leakage (Ichinose and Barnes, 1990; Ricciardolo et al., 1994) and bronchial hyperreactivity (Omini et al., 1989) ; furthermore in vitro evidence indicates that BK may stimulate inflammatory cells recruitment (Sato et al., 1996; Koyama et al., 2000) .
These effects are mediated by the B 2 receptor, also indirectly through the release of cyclooxygenase products and sensory nerve endings stimulation (Ichinose et al., 1990; Nakajima et al., 1994) . In man, BK induces potent bronchoconstriction and cough when inhaled in asthmatic patients (Polosa and Holgate, 1990; Choudry et al., 1989 ) and rhinitis-like symptoms when instilled into the nose (Churchill et al., 1991) .
Furthermore, BK is generated in human nasal secretions during rhinovirus infections (Shibayama et al., 1996) and allergic rhinitis (Svensson et al., 1990; Proud et al., 1983) . On the basis of these findings, a therapeutic potential role of kinin B 2 receptor antagonists has been hypothesized for the treatment of airways inflammatory pathologies associated with hyperresponsiveness to BK, such as chronic bronchial asthma (Akbary et al., 1996) , or with the release of BK, such as periennal and seasonal allergic rhinitis (Austin et al., 1994; Turner at al., 2001 ).
On the other hand, in addition to their proinflammatory activities, kinins also exert protective effects on the cardiovascular system. Several studies have provided evidence suggesting that BK contributes to the antihypertensive and cardioprotective effects of angiotensin-converting enzyme inhibitors (Kuoppala et al., 2000; Campbell et al., 2005) . In rat BK exerts an injury-limiting effect in the ischaemic and reperfused heart (Ito et al., 2003; Driamov et al., 2004) and acute cardiovascular effects produced by kinin B 2 receptor antagonists have been observed (Carini et al., 2002) .
On the basis of these considerations it would be important to obtain a block of B 2 receptors in the airways without interfering with those at cardiovascular level.
MEN16132 (Fig 1) is a new selective non-peptide antagonist of the kinin B 2 receptor endowed with high affinity for the guinea-pig and human receptors (Cucchi et al., submitted) . In this study we have investigated the ability of the new B 2 receptor antagonist, MEN16132, in inhibiting BK-induced bronchoconstriction or PPE in nasal mucosa after intravenous or local administration (aerosol, intratracheal or intranasal).
The peptide B 2 receptor antagonist Icatibant has been used as a reference compound. In order to check the systemic absorption after local administration of MEN16132, its effect on BK-induced hypotension was also determined.
series of experiments, aiming to check the duration of action of i.v. MEN 16132 on BK-induced bronchoconstriction, the observation period was prolonged to 8h. BK (10 nmol/kg i.v.) was administered every 1h in order to avoid possible tachyphylaxis.
In order to check the possibility of antagonist systemic absorption after intranasal application, MEN16132 or its vehicle (saline, 30 µl/nostril) were instilled in both nostrils of unanesthetized guinea-pigs. After 15 min the animals were anesthetized with urethane (1 g/kg i.p.). The trachea and carotid artery were cannulated for mechanical ventilation and blood pressure recording, respectively, as described above; 45 min after antagonist administration, BK (10 nmol/kg i.v.) was given and repeated twice at 30 min interval.
Nasal mucosa microvascular leakage induced by i.n. bradykinin MEN16132, Icatibant or their vehicle were instilled in a volume of 30 µl in both nostrils of unanesthetized guinea-pigs. After 10 min, the animals were anesthetized with sodium pentobarbital (40 mg/kg i.p.), the jugular vein was cannulated for drugs administration and the animals were mechanically ventilated through a tracheal cannula (10 ml/kg room air, 50 strokes/min). Guinea-pigs were pretreated (5 min before) with captopril (1 mg/kg i.v.) then, 30 min after antagonist, Evans blue (30 mg/kg i.v.) and BK (100 nmol/nostril) or its vehicle (saline, 30 µl/nostril) were administered.
A dose-response curve to i.n. BK was first obtained to select a dose suitable for evaluation of the antagonists activity.
After 15 min, the chest was opened, a cannula was inserted into the left ventricle and the circulation was perfused with 100 ml of saline containing heparin (180 IU/ml) in order to flush out the dye; the right atrium was opened to allow the expulsion of the perfusion medium. The nasal mucosa was removed and weighed. The Evans blue extravasated from the microcirculation was quantified by measuring the optical density of the formamide extracts (for 6h at 60°C) at 630 nm wavelength with a spectrophotometer (CERES UV900C, Biotek Instruments).
In order to determine the time-course of MEN16132 inhibition on BK-induced nasal mucosa PPE, the agonist was administered i.n. 3, 6, 9 or 15 h after i.n. antagonist. antagonists.
Drugs and Chemicals
Both MEN16132 and Icatibant, exerted a dose-dependent inhibition of BK-induced bronchoconstriction and hypotension when administered by the i.v. route ( Fig. 2 and 3).
The lowest effective dose of MEN16132 on bronchoconstriction was 3 nmol/kg i.v.
reaching about 50 % inhibition within 5 min with a recovery to 20 % inhibition within 60 min. At 10 and 30 nmol/kg i.v. the block became complete for 150 min and 210 min, respectively ( Fig. 2A) . The ID 50-Σ was 4.6±1.9 nmol/kg i.v. (Fig 4A) . MEN 16132 (30 nmol/kg i.v.), 8h after administration, still showed a strong (88±4%, n=4) inhibition of BK-induced bronchoconstriction. In control animals no significant tachyphylaxis was observed, the BK response being about 75% of the basal value at the end of the experiment (n=4, data not shown).
MEN16132 achieved a complete inhibition of BK-induced hypotension at 5 min from administration, at a dose of 30 nmol/kg i.v., but subsequently a time-dependent recovery of the BK response was observed; the lowest effective dose on BK-induced hypotension (producing 40% inhibition) was 10 nmol/kg i.v. (Fig. 2B ).
This article has not been copyedited and formatted. The final version may differ from this version. Icatibant produced a transient but deep (about 80%) inhibition of BK-induced bronchoconstriction at 10 nmol/kg i.v. At 30 nmol/kg i.v., Icatibant produced a complete inhibition of BK-induced bronchoconstriction, but this effect showed a strong tendency to reduce after 30 min from administration. A substantial recovery of the bronchoconstrictor response to BK was still evident at 300 nmol/kg i.v. (Fig. 3A) .
The calculated ID 50-Σ for Icatibant was 56.1±18.7 nmol/kg i.v. (Fig 4A) . Icatibant exerted about 80%, 40% and 20% inhibition of BK-induced hypotension at the doses of 300, 10 and 3 nmol/kg i.v., respectively. Also this effect was subjected to timedependent recovery of basal response, which was even more prominent than for bronchoconstriction ( Fig. 3B ).
After application into the airways by i.t. route, MEN16132 and Icatibant were able to inhibit the BK-induced bronchoconstriction in a dose-dependent manner ( Fig. 2 and   3 ).
MEN16132 produced a complete inhibition of bronchoconstriction at the dose of 100 nmol/kg i.t.. At the lower doses, 10 and 30 nmol/kg i.t., about 40% and 80% inhibition was observed, respectively, with an ID 50-Σ = 18±2 nmol/kg ( Fig 4B) . Independently from the dose, the inhibitory effect lasted for at least 210 min (Fig. 2C ). MEN16132
(10-100 nmol/kg i.t.) produced a significant inhibitory effect (55±13%) on BK-induced hypotension only at the highest dose tested and at 210 min the recovery of control response was almost complete (Fig. 2D) .
Icatibant, at 30, 100 and 300 nmol/kg i.t., inhibited by about 40%, 80% and 100% the BK-induced bronchoconstriction, respectively; a slow recovery of BK response was observed starting at 30 min from antagonist administration (Fig. 3C ). The ID 50-Σ was 130±21 nmol/kg ( Fig. 4B ). At 100 and 300 nmol/kg i.t., Icatibant exerted similar inhibitory effect on BK-induced hypotension: a maximal inhibition of about 45% was recorded at 5 min from its administration but the effect disappeared within 150 min.
At the lowest dose, 30 nmol/kg i.t., only a weak (20-30%) and transient inhibitory effect was observed (Fig. 3D ).
Aerosol administration of MEN16132 or Icatibant, produced a dose-dependent inhibition of BK-induced bronchoconstriction, without affecting the hypotension ( Fig. 2 and 3).
The inhalation of aerosolized 0.1 mM solution of MEN16132 for 5 min, reduced by about 80% the BK-induced bronchoconstriction for the whole experimental period, whereas 0.01 or 0.03 mM solution of MEN16132 produced inhibitory effects of about 20% and 40%, respectively (Fig. 2E ). The corresponding value of ID 50-Σ was 0.07±0.03 mM (Fig 4C) . Aerosolized MEN16132 did not exert any significant inhibitory effect on the BK-induced hypotension, at all concentrations (0.01-0.1 mM) tested (Fig. 2F ).
After inhalation of aerosolized 0.3, 1 or 3 mM solution of Icatibant for 5 min, a maximal inhibition on BK-induced bronchoconstriction of about 40%, 60% and 80%, was achieved in the first 30 min, respectively. An almost complete recovery of the basal response to BK was observed at the end of the experimental period (Fig. 3E ).
The ID 50-Σ was 1.4±0.3 mM aerosol for 5 min (Fig 4C) . The effect of aerosolized Icatibant on BK-induced hypotension did not exceed 30% inhibition at the highest concentration tested (Fig. 3F) .
Effect of intranasal MEN16132 on topical BK-induced nasal mucosa PPE
The i.n. instillation of BK (50-200 nmol/nostril, n=5) induced Evans blue PPE in the nasal mucosa in a dose-dependent manner. The effect produced by 50 nmol/nostril (35±1 ng/mg tissue) was about 30% of the maximal response observed at 100
This article has not been copyedited and formatted. The final version may differ from this version. At about 60 min from their administration, MEN16132 and Icatibant, at 0.3 and 10 nmol/nostril, respectively, abolished the BK-induced PPE; at 0.03 and 3 nmol/nostril for MEN16132 and Icatibant, a significant inhibition of BK response by about 55% and 70%, respectively, was still observed (Fig. 5) .
MEN16132 (0.3 nmol/nostril), at 3h from its i.n. administration, produced a still significant inhibitory effect (60%). At this time the i.n. application of MEN16132 (1 and 3 nmol/nostril), exerted a complete inhibition of BK-induced nasal mucosa PPE; this inhibitory effect was maintained at about 80% after 6h. At 10 nmol/nostril, MEN16132
blocked the PPE for 6h; a small recovery was observed after 9h, however at 15h the inhibitory effect was still about 60% (Fig. 6) .
Effect of intranasal MEN16132 on BK-induced hypotension
The local inhibitory effect exerted by MEN16132 (1 nmol/nostril) on nasal mucosa PPE, was not accompanied by systemic effects since no inhibition of hypotension induced by BK (10 nmol/kg i.v.) was observed. At the highest dose tested (10 nmol/nostril), MEN16132 showed only a weak systemic effect, exerting about 25% inhibition of BK-induced hypotension after 75 min from antagonist administration (Fig.   7 ).
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Discussion
MEN16132 is a new potent and selective non-peptide kinin B 2 receptor antagonist whose structure was designed for optimal pharmacological profile starting from known non-peptide ligands (LF16-0335C; Pruneau et al., 1999a) . The key structural features of MEN16132 are the conformationally constrained 4-amino-4-carboxytetrahydropyran and the basic charged N-δ-trimethyl-ornithine moiety (Fig 1) .
The combination of the above elements led to high affinity and potency at the human In a clinical study on inhibition of responses to nasal provocation with BK, Icatibant at 650 nmol/nostril has shown a short duration of action that could severely limit its utility in chronic rhinitis treatment (Proud et al., 1995) . MEN16132, as observed on BK-induced bronchoconstriction after aerosol administration, exerts a long lasting inhibition of BK-induced nasal mucosa PPE, being 30 fold more potent than Icatibant and maintaining an almost complete inhibitory effect up to 9 h at 10 nmol/nostril dose. This high potency, associated with a long duration of action, could be a favourable characteristic for clinical studies i.e. in rhinitis and in bronchoconstriction related to asthma.
In order to check the possibility of systemic absorption after local intranasal application of MEN16132, we have investigated the degree of inhibition on BKinduced hypotension. Considering the highest dose tested (10 nmol/nostril), which produces a strong and long lasting inhibitory effect on BK-induced nasal mucosa PPE and assuming that all the compound is absorbed at the same time, we could obtain an available dose in the blood of 20 nmol/animal. This dose is very close to were instilled in the nose of unanesthetized guinea-pigs. After 0.5, 3, 6, 9 or 15h, the animals were anesthetized and BK (100 nmol/nostril) was administered intranasally.
The effect of MEN16132 was reported as percent inhibition of control BK-induced increase of Evans blue in nasal mucosa at each time-point, normalized to the 
